Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S

Biologicals

Volumn 54, Issue , 2018, Pages 58-62

  Langenmayer, Martin C ^a,b   Lülf Averhoff, Anna Theresa ^a,b   Adam Neumair, Silvia ^a   Fux, Robert ^a,b   Sutter, Gerd ^a,b   Volz, Asisa ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Partner Site Munich   (Germany)

Author keywords

Biodistribution; Immunohistochemistry; MERS; PCR; Poxvirus vaccine; Vaccinia virus MVA; Viral vector

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA MERS S VACCINE; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; VACCINE; VIRUS ANTIGEN; VIRUS DNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HYPERPLASIA; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; INJECTION SITE INFLAMMATION; INOCULATION; LYMPH NODE HYPERPLASIA; LYMPHATIC DRAINAGE; MALE; MIDDLE EAST RESPIRATORY SYNDROME; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; MUSCLE NECROSIS; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TISSUE INJURY; VACCINATION; VACCINIA VIRUS; ANIMAL; CORONAVIRUS INFECTION; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS;

ANIMALS; CORONAVIRUS INFECTIONS; INJECTIONS, INTRAMUSCULAR; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VACCINATION; VACCINIA VIRUS; VIRAL VACCINES;

EID: 85046863894     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2018.05.004     Document Type: Article

References (15)

1. Mayr, A., Hochstein-Mintzel, V., Stickl, H., Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3 (1975), 6–14.
2. Volz, A., Sutter, G., Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res 97 (2017), 187–243.
3. Verheust, C., Goossens, M., Pauwels, K., Breyer, D., Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine 30 (2012), 2623–2632.
4. Sutter, G., Moss, B., Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89 (1992), 10847–10851.
5. Hanke, T., McMichael, A.J., Dennis, M.J., Sharpe, S.A., Powell, L.A., McLoughlin, L., et al. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 23 (2005), 1507–1514.
6. Hanke, T., McMichael, A.J., Samuel, R.V., Powell, L.A., McLoughlin, L., Crome, S.J., et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 21 (2002), 108–114.
7. Ondondo, B., Brennan, C., Nicosia, A., Crome, S.J., Hanke, T., Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice. Vaccine 31 (2013), 5594–5601.
8. Stittelaar, K.J., Kuiken, T., de Swart, R.L., van Amerongen, G., Vos, H.W., Niesters, H.G., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19 (2001), 3700–3709.
9. Sanchez-Sampedro, L., Perdiguero, B., Mejias-Perez, E., Garcia-Arriaza, J., Di Pilato, M., Esteban, M., The evolution of poxvirus vaccines. Viruses 7 (2015), 1726–1803.
10. Volz, A., Kupke, A., Song, F., Jany, S., Fux, R., Shams-Eldin, H., et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory Syndrome Coronavirus spike glycoprotein. J Virol 89 (2015), 8651–8656.
11. Haagmans, B.L., van den Brand, J.M., Raj, V.S., Volz, A., Wohlsein, P., Smits, S.L., et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351 (2016), 77–81.
12. Lülf, A.T., Freudenstein, A., Marr, L., Sutter, G., Volz, A., Non-plaque-forming virions of modified vaccinia virus Ankara express viral genes. Virology 499 (2016), 322–330.
13. Schroeder, K., Nitsche, A., Multicolour, multiplex real-time PCR assay for the detection of human-pathogenic poxviruses. Mol Cell Probes 24 (2010), 110–113.
14. Volz, A., Langenmayer, M.C., Jany, S., Kalinke, U., Sutter, G., Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara. J Virol 88 (2014), 10946–10957.
15. Valli, V.E.O., Kiupel, M., Bienzle, D., Hematopoietic system. Grant Maxie, M., (eds.) Jubb, Kennedy, and Palmer's pathology of domestic animals, 2016, Elsevier, St. Louis, 102–268.